T1	MajorClaim 1 95	The incidence and development of cancer are closely related to dysfunction of immune function.
T2	Premise 1003 1133	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
T3	Premise 1134 1275	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
T4	Premise 1276 1397	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
T5	Premise 1398 1524	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
T6	Claim 1525 1682	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
T7	Claim 1683 1794	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
R1	Support Arg1:T5 Arg2:T7	
R2	Support Arg1:T4 Arg2:T7	
R3	Support Arg1:T5 Arg2:T6	
R4	Support Arg1:T3 Arg2:T6	
R5	Support Arg1:T2 Arg2:T6	
R6	Support Arg1:T2 Arg2:T7	
